Digital Content 
NEWS #PharmaBuzz
17 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/17/3151402/0/en/Arcutis-To-Present-Multiple-New-ZORYVE-roflumilast-Data-Analyses-at-European-Academy-of-Dermatology-and-Venereology-Congress.html
16 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/16/3150850/0/en/Allure-Magazine-Honors-Arcutis-ZORYVE-roflumilast-with-Prestigious-Best-of-Beauty-Breakthrough-Award.html
03 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/03/3143886/0/en/Arcutis-Submits-Supplemental-New-Drug-Application-for-ZORYVE-roflumilast-Cream-0-3-to-Expand-Indication-for-Treatment-of-Plaque-Psoriasis-in-Children-Ages-2-to-5.html
10 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/10/3096580/0/en/Arcutis-Enrolls-First-Child-in-INTEGUMENT-INFANT-Evaluating-ZORYVE-roflumilast-Cream-0-05-in-Infants-with-Atopic-Dermatitis.html
06 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/06/3095048/0/en/Arcutis-to-Present-New-Long-Term-Results-of-ZORYVE-roflumilast-Cream-at-the-2025-Revolutionizing-Atopic-Dermatitis-Conference.html
22 May 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/05/22/3087008/0/en/Arcutis-ZORYVE-roflumilast-Topical-Foam-0-3-Approved-by-U-S-FDA-for-the-Treatment-of-Plaque-Psoriasis-in-Adults-and-Adolescents-Ages-12-and-Older.html
Share 